Physician profile
Nicole E Thurman
NPI 1659635464
$977.30
in general payments reported to CMS, 2019-2025
8 companies · $60.35 in 2025
The $60.35 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $228 · 2023: $139 · 2024: $143 · 2025: $60.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $623.84 | 2021-2025 | Yeztugo |
| Viiv Healthcare Company | $170.65 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $61.35 | 2021-2023 | Symtuza |
| Janssen Biotech, INC. | $39.66 | 2021 | |
| Celgene Corporation | $22.29 | 2022 | |
| Merck Sharp & Dohme LLC | $22.23 | 2021 | |
| Phadia US INC. | $21.24 | 2023 | Immunocap |
| Kci USA, INC. | $16.04 | 2023 | Kerramax Care, Silvercel, Promogran Prisma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Thurman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.